The agreement allows the GLP-1s to be covered by Medicaid to treat obesity, while it would require Medicare to cover the drugs for obese Americans who are also at high risk for other health problems
Any changes you notice on semaglutide can be measured against what is normal for your body specifically, not against population averages that may not apply to you
These developments highlight the shift in treatment goals for T2D, from primarily focusing on the management of hyperglycaemia to a greater appreciation of the importance of managing cardiorenal risk, to reduce the high rates of CV deaths and cardiorenal hospitalisations in patients with T2D
The side effects seen in the study were already well known from previous semaglutide research, including nausea and reduced appetite
For patients with a baseline BMI 35, discontinuation rates due to adverse events were 8.8% and 12.1% for the 9 mg and 12 mg doses, respectively, compared to 4.8% with placebo
Further trials will be crucial to confirm its long-term safety and efficacy across diverse patient populations and to explore its potential benefits in treating other metabolic conditions
